 Nuwellis

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Nuwellis reports revenue growth and margin improvement in Q1 2024

Nuwellis' Q1 2024 performance showed revenue growth driven by consumable utilization, improved margins, and reduced operating losses. Challenges in critical care revenue persist, but expense reductions and growth opportunities in pediatrics signal a positive outlook.

Nuwellis reports revenue growth and operational improvements in Q2 2024

Nuwellis (NUWE) showed improved financial performance in Q2 2024 with revenue growth and reduced operating loss, despite challenges in the pediatric segment.
The company's strengths lie in successful product launches, financial stability, and increasing market presence, while facing challenges in pediatric revenue and R&D expenses.
Opportunities for Nuwellis include leveraging positive momentum, expanding product adoption, and capitalizing on its strong financial position for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MINNEAPOLIS, July 14, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its second quarter 2022 financial results will be released on Tuesday, August 9, 2022. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit https://edge.media-server.com/mmc/p/frxpm437 [edge.media-server.com], or the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by registering through https://register.vevent.com/register/BIea28b3e149034b04b99b65da059db74a. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.

Nuwellis, Inc. To Announce Second Quarter 2022 Financial Results on August 9, 2022

MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on improving the quality of life for people with fluid overload, today announced key takeaways from its recent physician-led webinar discussing the benefits of treating fluid overloaded heart failure (HF) patients with Aquadex® ultrafiltration (UF) in the outpatient setting – the first step toward commercializing this opportunity.

Nuwellis Initiates Its Outpatient Heart Failure Strategy Using Aquadex Ultrafiltration Therapy

REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload

Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF

Pediatric Segment Growth Continues at 36% CAGR Pediatric Segment Growth Continues at 36% CAGR

Nuwellis Expands Pediatric Access to Ultrafiltration Therapy at Hospitals in Florida and Arkansas

MINNEAPOLIS, May 17, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that the Company's 2022 Annual Meeting of Stockholders, on May 17, 2022 at 2:00 p.m., was convened and adjourned, without any business being conducted, due to lack of the required quorum.

Nuwellis, Inc. Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum

Nuwellis, Inc. (NASDAQ:NUWE ) Q1 2022 Earnings Conference Call May 10, 2022 9:00 AM ET Company Participants Matthew Bacso - Gilmartin Group Nestor Jaramillo - President, CEO & Director George Montague - CFO Conference Call Participants Destiny Buch - Ladenburg Thalmann & Co. Anthony Vendetti - Maxim Group Operator Good day and thank you for standing by. Welcome to the Nuwellis, Inc. First Quarter 2022 Earnings.

Nuwellis, Inc. (NUWE) CEO Nestor Jaramillo on Q1 2022 Results - Earnings Call Transcript

MINNEAPOLIS, May 10, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the first quarter ended March 31, 2022, which included the following highlights:

Nuwellis, Inc. Announces First Quarter 2022 Financial Results

New Data Adds to the Growing Body of Research Supporting the Negative Impact of Fluid Overload, Therapies to Prevent Kidney Injury and the Use of Ultrafiltration for Varying Patient Populations New Data Adds to the Growing Body of Research Supporting the Negative Impact of Fluid Overload, Therapies to Prevent Kidney Injury and the Use of Ultrafiltration for Varying Patient Populations

Nuwellis Announces Presentation of Aquadex®-Related Abstracts at the 2022 Pediatric Academic Societies Meeting

The REVERSE-HF study will evaluate ultrafiltration therapy for heart failure patients suffering from fluid overload The REVERSE-HF study will evaluate ultrafiltration therapy for heart failure patients suffering from fluid overload

Nuwellis Announces IRB Approval to Begin Its REVERSE-HF Clinical Study

Nuwellis' (NUWE) CEO Nestor Jaramillo on Q4 2021 Results - Earnings Call Transcript

MINNEAPOLIS, March 01, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the fourth quarter and full year ended December 31, 2021, which included the following highlights:

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results

REVERSE-HF will evaluate rehospitalizations and survival when using the Aquadex therapy REVERSE-HF will evaluate rehospitalizations and survival when using the Aquadex therapy

Nuwellis Initiates REVERSE-HF Study to Evaluate Ultrafiltration for Heart Failure Patients with Fluid Overload

MINNEAPOLIS, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its fourth quarter 2022 financial results will be released on Tuesday, March 1, 2022. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.

Nuwellis, Inc. to Announce Fourth Quarter 2021 Financial Results on March 1, 2022

The code expands access to lifesaving, novel fluid overload treatment The code expands access to lifesaving, novel fluid overload treatment

New Category III CPT Code for the Nuwellis Aquadex Ultrafiltration System is Now in Effect

MINNEAPOLIS, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective November 17, 2021, the independent directors approved an equity award under Nuwellis' 2021 Inducement Plan, as a material inducement to an individual entering into employment with the company. The equity award was approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

Nuwellis, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Nuwellis, Inc. (NUWE) CEO Nestor Jaramillo on Q3 2021 Results - Earnings Call Transcript

MINNEAPOLIS, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the third quarter ended September 30, 2021, which included the following highlights:

Nuwellis, Inc. Announces Third Quarter 2021 Financial Results

EDEN PRAIRIE, Minn., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) was honored at the 2021 R&D 100 Awards last month, with its Aquadex SmartFlow® system selected as a winner in the Analytical/Test category. The awards, presented by R&D World, recognize commercial products, technologies and materials for their technological significance that are available for sale or license. This renowned worldwide competition is its 59th year and received entries from 17 countries/regions. This year, the judging panel included nearly 40 well-respected industry professionals from across the globe.

Aquadex SmartFlow® System by Nuwellis Selected as a 2021 R&D 100 Awards Winner

EDEN PRAIRIE, Minn., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE), announced today that its third quarter 2021 financial results will be released on Tuesday, November 9, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.

Nuwellis, Inc. To Announce Third Quarter 2021 Financial Results on November 9, 2021

Nuwellis Inc (NASDAQ:NUWE) has received CE Mark Certification for its 24-Hour Blood Circuit Set (UF 500-24 Hour) for the European Union. The UF 500-24 Hour blood circuit set is only to be used with the company's Aquadex SmartFlow system.

Nuwellis Stock Is Moving Higher After CE Mark for 24-Hour Blood Circuit Set

Certification will help Nuwellis meet clinical and healthcare economic needs in Europe and make outpatient ultrafiltration treatment more accessible Certification will help Nuwellis meet clinical and healthcare economic needs in Europe and make outpatient ultrafiltration treatment more accessible

Nuwellis Receives CE Mark for 24-Hour Blood Circuit Set

EDEN PRAIRIE, Minn., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) (the “Company”) announced today the closing of its previously announced underwritten public offering of 4,005,588 shares of its common stock at a price to the public of $2.50 per share, for gross proceeds of approximately $10.0 million, including the full exercise of the underwriters' over-allotment option to purchase additional shares of the Company's common stock, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.

Nuwellis, Inc. Announces Closing of $10.0 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option

Nuwellis (NASDAQ:NUWE) shares are trading lower after the company announced it priced a 3,483,120 share common stock offering at $2.50 per share. Nuwellis' stock has been falling Wednesday, down 28.46% to a price of $2.64.

Why Nuwellis Shares Are Trading Lower Today

EDEN PRAIRIE, Minn., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) (the “Company”) announced today the pricing of an underwritten public offering of 3,483,120 shares of its common stock at a price to the public of $2.50 per share, for gross proceeds of approximately $8.7 million prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.  The Company has granted the underwriters an option, exercisable in whole or in part for 45 days, to purchase up to an additional 522,468 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Nuwellis, Inc. Announces Pricing of $8.7 Million Underwritten Public Offering of Common Stock

EDEN PRAIRIE, Minn., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) (the “Company”) announced today that it intends to offer shares of its common stock in an underwritten public offering.  All of the shares of common stock to be sold in the offering will be offered by the Company.  The Company intends to grant the underwriters a 45-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.  The Company intends to use the net proceeds for the offering for general corporate purposes, including the continued investment in commercialization efforts. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

News for Nuwellis Stock (NUWE)